SPT Labtech, a global leader in the design, development and manufacture of automated instrumentation and consumables for life science applications, is pleased to announce a partnership with BioLabs, the global innovation support platform.

Today, family-run community pharmacy chain Jardines Pharmacy (“Jardines”), primarily based in Milton Keynes and Bedfordshire, announces the launch of the Jardines Pharmacy app in collaboration with Charac, the UK’s premier patient relationship management platform for pharmacies. Charac’s platform will help Jardines digitalise its services, improving operational effectiveness and customer satisfaction.

Regeneron Pharmaceuticals, Inc today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference in Baltimore, Maryland, from May 7 to 11, 2024.

Next Ilmac in Lausanne: 18 and 19 September 2024 | Beaulieu Lausanne Next Ilmac in Basel: 16 - 18 September 2025 | Messe Basel, Hall 1.0 All information at: www.ilmac.ch

The European Laboratory Research & Innovation Group (ELRIG) UK, a not-for-profit, volunteer-led organisation for the drug discovery community, today entered into a partnership with SRG, leaders in life science recruitment, to support the advancement of science professionals in their careers.

INTERPHEX, the premier pharmaceutical and biotechnology event taking place April 16-18, 2024, at the Javits Center in NYC, is proud to introduce INTERPHEX Conference, an all-new, transformative event that will enrich the meeting experience for attendees, starting in 2024.

A variety of factors like powder flow, material characteristics, compression pressure, turret speed, etc can affect tablet quality and production run time. Any resulting tablet defects can exacerbate production costs or even result in no product at all! Therefore, it’s necessary to characterise the tablet compression process to achieve robust tablets.

: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases. The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.

Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the introduction of the AugaOne™ sensor system. AugaOne is the first product in the Company’s sensor system platform, Auga™, and is tailored to accelerate downstream monoclonal antibody (mAb) process development by providing specific real-time and automated in-line data with high sensitivity, without requiring sample pretreatment.

Between 6-10th November 2023, a five-day inspection was undertaken, which concluded successfully with no critical and no major observations raised. A Good Manufacturing Practice (GMP) certificate has been granted to the site by the authority

Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today introduced its SemaCyte® Multiplexing Platform, an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery.